Bristol-Myers Squibb Co (XTER:BRM)
€ 38.14 -0.525 (-1.36%) Market Cap: 77.32 Bil Enterprise Value: 121.47 Bil PE Ratio: 0 PB Ratio: 5.07 GF Score: 73/100

bluebird bio Inc and Bristol-Myers Squibb Co to Provide Regulatory Update on Idecabtagene Vicleucel - Conference Call Transcript

May 13, 2020 / 12:45PM GMT
Release Date Price: €58.62 (-0.34%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Bluebird Bio Regulator Update Call. (Operator Instructions)

I would now like to hand the conference over to your speaker, Ingrid Goldberg. Please go ahead.

Ingrid Goldberg
bluebird bio, Inc. - VP of IR

Thank you. Good morning, everyone, and thank you for joining today's call. The format for today's call will be brief opening remarks from Nick. And then for the Q&A portion, we'll be joined by Dave and Chip as well as our Chief Business Officer and Head of Oncology, Joanne Smith-Farrell; and Chief Technology and Manufacturing Officer, Derek Adams.

Before we begin, I would like to remind everyone that we will make statements about the company's future plans and prospects that constitute forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in today's SEC filings. These forward-looking statements represent our estimates as of today and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot